Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate
Icosavax, Inc. announced the first subjects have been dosed with IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD), in a Phase 1/2 clinical…
Read More...
Read More...
